This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Health Policy  • Women's Health, Other  • Alert me on articles by topic

Tracy Hampton, PhD

JAMA. 2005;294:1481.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Susan Wood, PhD, director of FDA’s Office of Women's Health and assistant commissioner for women’s health, has resigned following the FDA’s announcement in late August that it would delay a decision on whether to allow the morning-after pill, called Plan B, to be sold without a prescription.

The FDA stated that its drug center had concluded that the available scientific data were sufficient to support the safe use of Plan B as an over-the-counter product for women who are 17 years of age and older. But because of unresolved regulatory and policy issues, the agency said it would begin another regulatory process and hold a new 60-day public comment period.

"The recent decision announced by the Commissioner about emergency contraception, which continues to limit women's access to a product that would reduce unintended pregnancies and reduce abortions is contrary to my core commitment to improving and advancing . . . [Full Text of this Article]